Eph receptor tyrosine kinases in tumor and tumor microenvironment

Current Pharmaceutical Design

Volumn 10, Issue 27, 2004, Pages 3431-3442

  Brantley Sieders, Dana ^a   Schmidt, Sonja ^a   Parker, Monica ^a   Chen, Jin ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANTINEOPLASTIC AGENT; CYTOKINE; EPHRIN; EPHRIN A1; EPHRIN A2; EPHRIN A3; EPHRIN A4; EPHRIN RECEPTOR; EPHRIN RECEPTOR A8; EPHRIN RECEPTOR B1; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B3; EPHRIN RECEPTOR B4; EPHRIN RECEPTOR B5; EPHRIN RECEPTOR B6; LIGAND; PEPTIDE DERIVATIVE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER INFILTRATION; CELL INTERACTION; CELL TRANSPORT; COLON CANCER; DATA ANALYSIS; DRUG DESIGN; DRUG TARGETING; EMBRYO DEVELOPMENT; EMBRYO PATTERN FORMATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; KIDNEY TUMOR; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MELANOMA CELL; MICROENVIRONMENT; NERVE CELL; NEUROBLASTOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; EPHRINS; HUMANS; LIGANDS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION;

EID: 4644290521     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383160     Document Type: Review

References (122)

1. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F. A novel putative tyrosine kinase receptor encoded by the cph gene. Science 1987; 238: 1717-1720.
2. Holder N and Klein R. Eph receptors and ephrins: effectors of morphogenesis. Development 1999; 126: 2033-44.
3. Kullander K and Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 2002; 3: 475.
4. Flanagan JG, Vanderhaeghen P. The ephrins and Eph receptors in neural development. Annu Rev Neurosci 1998; 21: 309-45.
5. Cheng N, Brantley D, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine and Growth Factor Reviews 2002; 13: 75-85.
6. Nakamoto M, Bergmann A. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microscopic Research and Technique 2002; 59: 58-67.
7. Gale NW, Holland SJ, Valenzuela DM, Flenniken A, Pan L, Ryan TE, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996; 17: 9-19.
8. Committee EN. Unified nomenclature for Eph family receptors and their ligands, the Ephrins. Cell 1997; 90: 403-404.
9. Torres R, Firestein BL, Dong H, Staudinger J, Olson EN, Huganir RL, et al. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Cell 1998; 21: 1453-1463.
10. Bruckner K, Labrador JP, Scheiffele P, Herb A, Seeburg PH, Klein R. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron 1999; 22: 511-524.
11. Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. Crystal structure of an Eph receptor-ephrin complex. Nature 2001; 414: 933-938.
12. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001; 106: 745-757.
13. Murai KK, Pasquale EB. 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 2003; 116: 2823-32.
14. Hock B, Bohme B, Karn T, Yamamoto T, Kaibuchi K, Holtrich U, et al. PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc Natl Acad Sci USA 1998; 95: 9779-9784.
15. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001; 114: 2713-22.
16. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62.
17. Shamah MS, Lin MZ, Goldberg JL, Estrach S, Sahin M, Hu L, et al. EphA receptors regulate growth cone dynamics through the novel guanine nucletide exchange factor ephexin. Cell 2001; 105: 233-44.
18. Ogita H, Kunimoto S, Kamioka Y, Sawa H, Masuda M, Mochizuki N. EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells. Circ Res 2003; 93: 23-31.
19. Deroanne C, Vouret-Craviari V, Wang B, Pouyssehur J. EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci 2003; 116: 1367-76.
20. Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, et al. Eprin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signaling. J Cell Sci 2002; 115: 1059-1072.
21. Brantley-Sieders D, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2003; 117: 2037-2049.
22. Miao H, Nickel CH, Cantley LG, Bruggeman LA, Bennardo LN, Wang B. EphA kinase activation regulates HGF-induced epithelial branching morphogenesis. J Cell Biol 2003; 162: 1281-92.
23. Irie F and Yamaguchi Y. EphB receptors regulate dendritic spine development via intersectin, Cdc42 and N-WASP. Nat Neurosci 2002; 5: 1117-8.
24. Penzes P, Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains RE, et al. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron 2003; 37: 263-274.
25. Marston DJ, Dickinson S, Nobes CD. Rac-dependent transendocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat Cell Biol 2003; 5: 879-88.
26. Elowe S, Holland SJ, Kulkarni S, Pawson T. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 2001; 21: 7429-7441.
27. Miao H, Wei B-R, Peehl DM, Li Q, Alexandrou T, Schelling JR, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nature Cell Biol 2001; 13: 527-530.
28. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002; 21: 7690-7699.
29. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nature Cell Biology 2000; 2: 62-69.
30. Carter N, Nakamoto T, Hirai H, Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 2002; 4: 565-573.
31. Bruckner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 1997; 275: 1640-1643.
32. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T. Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 1996; 383: 722-725.
33. Palmer A, Zimmer M, Erdmann KS, Eulenburg V, Porthin A, Heumann R, et al. EphrinB phophorylation and reverse signaling: regulation by src kinases and PTP-BL phosphatase. Molecular Cell 2002; 9: 725-737.
34. Cowan CA, Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 2001; 413: 174-179.
35. Lu Q, Sun EE, Klein RS, Flanagan JG. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G-coupled chemoattraction. Cell 2001; 105: 69-79.
36. Huynh-Do U, Vindis C, Liu H, Cerretti DP, McGrew JT, Enriquez M, et al. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci 2002; 115: 3073-3081.
37. Davy A, Nicholas WG, Murray EW, Klinghoffer RA, Soriano P, Feuerstein C, et al. Compartmentalized signaling by GPI-anchored ephren-A5 requires the Fyn tyrosine knase to regulate cellular adhesion. Genes & Development 1999; 13: 3125-3135.
38. Davy A, Robbins SM. EphrinA5 modultes cell adhesion and morphology in an integrin-dependent manner. EMBO J 2000; 19: 5346-406.
39. Huai J, Drescher U. An ephrinA dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120 kDa protein. J Biol Chem 2001; 276: 6689-6694.
40. Mellitzer G, Xu Q, Wilkinson DG. Eph receptors and ephrins restrict cell intermingling and communication. Nature 1999; 400: 77-81.
41. Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, Klein R. The cytoplasmic domain of the ligand ephrinB2 is required for vascualr morphogenesis but not cranial neural crest migration. Cell 2001; 104: 57-69.
42. Maru Y, Hirai H, Yoshida MC, Takaku F. Evolution, expression and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol Cell Biol 1988; 8: 3770-3776.
43. Maru Y, Hirai H, Takaku F. Overexpression confers an oncogenic potential upon the eph gene. Oncogene 1990; 5: 445-447.
44. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saurabh S, et al. Mutational anaysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
45. Andres A-C, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994; 9: 1461-1467.
46. Nikolova Z, Djonov V, Zuercher G, Andres A, Ziemiecki A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mamary gland morphogenesis. J Cell Sci 1998; 111: 2741-2751.
47. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, et al. Soluble EphA receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-7026.
48. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301-2306.
49. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 6043-52.
50. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2001; 2: 15.
51. Berclaz G, Karamitopoulou E, Mazzucchelli L, Rohrbach V, Dreher E, Zierniecki A, et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003; 14: 220-6.
52. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep 2001; 8: 567-73.
53. Berclaz G, Flutsch B, Altermatt HJ, Rohrbach V, Djonov V, Ziemiecki A, et al. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 2003; 9: 985-9.
54. Munarini M, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S, et al. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 2002; 115: 25-37.
55. Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996; 12: 169-76.
56. Giunciuglio D, Culty M, Fassina G, Masiello L, Melchiori A, Paglialunga G, et al. Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 1995; 63: 815-22.
57. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002; 94: 934-9.
58. Battle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huts G, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-63.
59. Easty D, Guthrie B, Maung K, Farr CJ, Lindberg RA, Toso RJ, et al. Protein B61 as a new growth factor: expression of B61 and upregulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995; 55: 2528-2532.
60. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates teh function of the EphA2 receptor tyrosine kinase. Cell Growth & Differentiation 1999; 10: 629-638.
61. Easty D, Hill S, Hsu M, Fallowfield M, Florenes V, Herlyn M, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999; 84; 494-501.
62. Orsulic S, Kemler R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000; 113: 1793-802.
63. Jones TL, Chong LD, Kim J, Xu RH, Kung HF, Daar IO. Loss of cell adhesion in Xenopus laevis embryos mediated by the cytoplasmic domain of XLerk, an erythropoietin-producing hepatocellular ligand. Proc Natl Acad Sci USA 1998; 95: 576-81.
64. Winning RS, Scales JB, Sargent TD. Disruption of cell adhesion in Xenopus embryos by Pagliaccio, an Eph-class receptor tyrosine kinase. Dev Biol 1996; 179: 309-19.
65. Zhou JX, Wang B, Kato MS, Zisch AH, Pasquale EB, Ruoslahti E. An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 1999; 96.
66. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93: 741-753.
67. Daniel TO, Stein E, Cerretti DP, John PL, Robert B, Abrahamson DR. Elk and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int Suppl 1996; 57: S73-81.
68. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes & Development 1999; 3: 295-306.
69. McBride JL, Ruiz JC. ephrinA1 is expressed at sites of vascular development in the mouse. Mech Dev 1998; 77: 201-204.
70. Pandey A, Shao H, Marks RM. Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α -induced angiogenesis. Science 1995; 268: 567-569.
71. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Molecular Cell 1999; 4: 403-414.
72. Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, et al. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 2001; 230: 139-50.
73. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2001; 230: 151-60.
74. Cheng N, Brantley D, Liu H, Fanslow W, Cerretti DP, Reith AD, et al. Inhibition of VEGF-depedent multi-stage carcinogenesis by soluble EphA receptors. Neoplasia 2003: (in press).
75. Chen J, Nachebeh A, Scherer C, Ganju P, Reith A, Bronson R, et al. Germline inactivation of the murine Eck receptor tyrosine kinase by retroviral insertion. Oncogene 1990; 12: 979-988.
76. Naruse-Nakajima C, Asano M, Iwakura Y. Involvement of EphA2 in the formation of the tail notochord via interaction with ephrinA1. Mech Dev 2001; 102: 95-105.
77. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale NW, et al. Blockade of EphA receptor tyrosine kinase activation inhibits VEGF-mduced angiogenesis. Mol Cancer Res (formerly Cell Growth and Differentiation) 2002; 1: 2-11.
78. Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T. A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes. Blood 2000; 95: 221-30.
79. Aasheim HC, Terstappen LW, Logtenberg T. Regulated expression of the Eph-related receptor tyrosine kinase Hek11 in early human B lymphopoiesis. Blood 1997; 90: 3613-22.
80. Boyd AW, Ward LD, Wicks IP, Simpson RJ, Salvaris E, Wilks A, et al. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem 1992; 267: 3262-7.
81. Wicks IP, Wilkinson D, Salvaris E, Boyd AW. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci USA 1992; 89: 1611-5.
82. Vergara-Silva A, Schaefer KL, Berg LJ. Compartmentalized Eph receptor and ephrin expression in the thymus. Mech Dev 2002; 119 Suppl 1: S225-9.
83. Munoz JJ, Alonso-C LM, Sacedon R, Crompton T, Vicente A, Jimenez E, et al. Expression and function of the Eph A receptors and their ligands ephrins A in the rat thymus. J Immunol 2002; 169: 177-84.
84. Sharfe N, Freywald A, Toro A, Dadi H, Roifman C. Ephrin stimulation modulates T cell chemotaxis. Eur J Immunol 2002; 32: 3745-55.
85. De Saint-Vis B, Bouchet C, Gautier G, Valladeau J, Caux C, Garrone P. Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin. Blood 2003; (in press).
86. Luo H, Yu G, Wu Y, Wu J. EphB6 crosslinking results in costimulation of T cells. J Clin Invest 2002; 110: 1141-50.
87. Freywald A, Sharfe N, Rashotte C, Grunberger T, Roifman CM. The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses. J Biol Chem 2003; 278: 10150-6.
88. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002; 62: 2840-7.
89. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002: 46974-9.
90. Walker-Daniels J, Riese DJ, Kinch MS. c-Cbl dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002; 1: 79-87.
91. Kikawa K, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002; 277: 39274-39279.
92. Pandey A, Lazar DF, Saltiel AR, Dixit VM. Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem 1994; 269: 30154-7.
93. Pandey A, Duan H, Dixit VM. Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase. J Biol Chem 1995; 270: 19201-4.
94. Yu HH, Zisch AH, Dodelet VC, Pasquale EB. Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor. Oncogene 2001; 20: 3995-4006.
95. Zisch AH, Kalo MS, Chong LD, Pasquale EB. Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region. Oncogene 1998; 16: 2657-70.
96. Ellis C, Kasmi F, Ganju P, Walls E, Panayotou G, Reith AD. A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Oncogene 1996; 12: 1727-1736.
97. Dodelet VC, Pazzagli C, Zisch AH, Hauser CA, Pasquale EB. A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A. J Biol Chem 1999; 274: 31941-6.
98. Choi S, Park S. Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn binding to the Tyr-615 site by enhancing tyrosine kinase activity. Oncogene 1999; 18: 5413-22.
99. Gu C, Park S. The EphA8 receptor regulates integrin activity through p110γ phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol Cell Biol 2001; 21: 4579-97.
100. Stein E, Cerretti DP, Daniel TO. Ligand activation of Elk receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J Biol Chem 1996; 271: 23588-23593.
101. Han DC, Shen TL, Miao H, Wang B, Guan JL. EphB1 associates with Grb7 and regulates cell migration. J Biol Chem 2002; 277: 45655-61.
102. Stein E, Lane AA, Cerretti DP, Schoeklmann HO, Schroff AD, Van Etten RL, et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment and assembly responses. Genes and Dev 1998; 12: 667-78.
103. Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO. Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 1998; 273: 1303-8.
104. Asundi VK, Carey DJ. Phosphorylation of recombinant N-syndecan (syndecan 3) core protein. Biochem Biophys Res Commun 1997; 240: 502-6.
105. Hock B, Bohme B, Karn T, Feller S, Rubsamen-Waigmann H, Strebhardt K. Tyrosine-614, the major autophosphorylation site of the receptor tyrosine kinase HEK2, functions as multi-docking site for SH2-domain mediated interactions. Oncogene 1998; 17: 255-60.
106. Tanaka M, Kamo T, Ota S, Sugimura H. Association of Dishevelled with Eph tyrosine kinase receptor and ephrin mediates cell repulsion. EMBO J 2003; 22: 847-58.
107. Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, et al. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 1997; 16: 3877-88.
108. Ethell IM, Irie F, Kato MS, Couchman JR, Pasquale EB, Yamaguchi Y. EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron 2001; 31: 1001-13.
109. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000; 10: 401-11.
110. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61: 3250-5.
111. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DC, Snyder P, et al. Overexpression of EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41: 275-280.
112. Rosenberg IM, Goke M, Kanai M, Reinecker HC, Podolsky DK. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997; 273: G824-32.
113. Kinch MS, Moore MB, Harpole DHJ. Predictive value of the EphA2 receptor tyrosine kinase in long cancer recurrence and survival. Clin Cancer Res 2003; 9: 613-8.
114. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE, Kinch MS, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001; 72: 1144-8.
115. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60: 4855-63.
116. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY, et al. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994; 54: 3645-50.
117. Chaib H, Cockrell EK, Rubin MA, Macoska JA. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 2001; 3: 43-52.
118. Bennett BD, Wang Z, Kuang WJ, Wang A, Groopman JE, Goeddel DV, et al. Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem 1994; 269: 14211-8.
119. Vogt T, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, et al. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998; 4: 791-7.
120. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
121. McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Design 2003; 9(31): 2593-613.
122. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Design 2003; 9(11): 891-902.